Overview
Overview
MOTS-c is a 16–amino-acid mitochondrial-derived peptide (MDP) that acts as a metabolic regulator, primarily through AMPK activation[1][2]. Preclinical studies show it enhances insulin sensitivity, promotes fat oxidation, improves exercise capacity, and counters age-related metabolic decline[1][4]. No clinical trials have been completed in humans to date[8]. This educational protocol presents a once-daily subcutaneous approach with gradual titration. Reconstitute: Add 3.0 mL bacteriostatic water
- Category
- Weight Loss
- Routes
- subcutaneous
Mechanism
MOTS-C
Mechanism of action
Mechanism of action
MOTS-c is encoded by mitochondrial DNA , not the DNA in the cell nucleus. That makes it part of a small group called mitochondria-derived peptides. Your body makes more of it during exercise and physical stress, and levels drop with age. The most studied effect is AMPK activation . AMPK is an enzyme that acts like an energy switch. When AMPK turns on, cells take in more glucose, burn more fat for fuel, and build more mitochondria over time. Lee and colleagues described this pattern in a 2015 paper in Cell Metabolism using mouse and cell models. The authors compared the metabolic profile to the diabetes drug metformin, but stopped short of saying the two are interchangeable. Reynolds and colleagues then showed in a 2021 Nature Communications paper that MOTS-c improved running capacity in young, middle-aged, and older mice, which is why some clinic and community sources call it an exercise-mimetic. That label overstates the human evidence: no published human randomized trial has reproduced the running-capacity effect.
Key research findings
- 01
MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded within the mitochondrial 12S rRNA region, studied as a regulator of metabolic homeostasis (mechanistic / in vitro).
- 02
In cell and mouse studies, MOTS-c is associated with AMPK pathway activation and improved insulin sensitivity, including in diet-induced obese mice (in vitro / animal model; Lee et al., Cell Metabolism, 2015).
- 03
MOTS-c has been described translocating to the nucleus under metabolic stress to influence adaptive gene expression (in vitro / animal model).
- 04
Exercise research reports changes in circulating MOTS-c with physical activity, suggesting an association with exercise physiology (human observational / animal model).
- 05
Direct human interventional trials for weight endpoints are not established; the weight-related evidence base is preclinical.
Primary source: Human evidence (limited): Domin and colleagues (2023, International Journal of Molecular Sciences ) reported that higher serum MOTS-c levels correlated with greater lower-body muscle strength in healthy adults. This is a correlation in one small sample, not a randomized intervention trial. Phase 1 analog data: CB4211, a synthetic MOTS-c analog, completed a Phase 1a/1b trial reported as safe and well tolerated. The molecule is related but not identical, so this safety signal does not transfer fully to native MOTS-c. Preclinical evidence (strongest): Lee and colleagues (2015, Cell Metabolism ) showed MOTS-c reduced obesity and insulin resistance in mice on a high-fat diet. Reynolds and colleagues (2021, Nature Communications ) showed running capacity improvement across mouse age groups. Kumagai and colleagues (2021, American Journal of Physiology - Endocrinology and Metabolism ) reported reduced myostatin and atrophy signaling in mice. Yi and colleagues (2023, Frontiers in Physiology ) reviewed bone-metabolism findings. Mechanism review: Wan and colleagues (2023, Journal of Translational Medicine ) and Kong and colleagues (2023, Diabetes & Metabolism Journal ) reviewed AMPK activation, mitochondria-to-nucleus signaling, and the link between MOTS-c and aging-related metabolic disease. Evidence gap: No published human randomized controlled trial has tested native MOTS-c for any clinical endpoint. Treat the dose tiers on this page as research-planning context, not as proof of human benefit.
Pharmacokinetic profile
Single-dose plasma curve over 24h. Shaded band = commonly-cited therapeutic window. Illustrative only.
Protocol Reference
Protocol reference
Commonly cited research range: 500–2000 mcg, daily_for_cycles.
Reference figures reported in the research literature — not a dosing recommendation. For interactive vial math and scheduling, see the Calculator and Schedule tabs.
Cited protocol & reconstitution guide
Source-backed reference fields by phase, including any volume fields authored in the cited guide.
Weeks 1–4 (Lower-end starting tier, 2x per week)
5 mg
Weeks 1–6 (Standard tier, 3x per week)
5 mg
Weeks 1–8 (Higher tier, 2-3x per week)
10 mg
| Phase | Reference amount | Units / volume |
|---|---|---|
| Weeks 1–4 (Lower-end starting tier, 2x per week) | 5 mg | 50 units (0.50 mL) |
| Weeks 1–6 (Standard tier, 3x per week) | 5 mg | 50 units (0.50 mL) |
| Weeks 1–8 (Higher tier, 2-3x per week) | 10 mg | 100 units (1.00 mL) |
Titration protocol
- 4 weeksStart5 mg
2x per week (not daily), subcutaneous. One 5 mg dose = the full reconstituted vial (0.5 mL). Rotate injection sites. Missed dose: skip it and resume at the next scheduled dose rather than doubling. Conservative cycle: 4 weeks on / 4 weeks off.
- 4-6 weeksBuild5 mg
3x per week; space doses evenly across the week. One 5 mg dose = the full reconstituted vial (0.5 mL). Standard cycle: 6 weeks on / 4-6 weeks off.
- 6-8 weeksMaintenance10 mg
2-3x per week. A 10 mg dose exceeds one 5 mg vial: two reconstituted 5 mg vials (0.5 mL each, 100 units total) are required per dose. Hold at the previous tier before moving up. Extended cycle: 8 weeks on / 6-8 weeks off.
Storage & Handling
Storage requirements(typical for most peptides)
Can be stored for extended periods. Protect from moisture.
Store in refrigerator door. Never freeze after reconstitution.
Label vials with reconstitution date. Discard if cloudy.
Reconstitution steps
- 01🌡️Inspect the vial: confirm label, listed peptide amount, and powder appearance (small white plug or fine cake)
- 02🧴Wipe both the bacteriostatic water vial and MOTS-c vial stoppers with a fresh alcohol swab
- 03💉Draw 1 mL bacteriostatic water into a sterile syringe — this 10 mg vial yields 10 mg/mL.
- 04💧Add water slowly: let it trickle down the inside wall of the vial; do not blast directly onto the powder
- 05🔄Swirl gently in slow circles until dissolved; do not shake
- 06🏷️Check the solution: clear and free of particles; do not use if cloudy or with visible specks
- 07❄️Refrigerate at 36-46F (2-8C), note the reconstitution date on the label, and use within 2-3 weeks
- 08💉Important: This guide is for educational purposes only and is not medical advice. MOTS-c is an experimental compound for research use only. Not for human consumption.
Additional storage notes
Store at −20 °C (−4 °F) or below in dry, dark conditions; include desiccant if available to minimize moisture exposure.
Refrigerate at 2–8 °C (35.6–46.4 °F); peptide degrades rapidly at room temperature (~25% activity loss after 24 hours at 4 °C) [7] . Use within 7 days for best potency.
Prepare single-use aliquots and freeze at −20 °C (−4 °F) if needed; avoid freeze–thaw cycles .
Allow vials to reach room temperature before opening to reduce condensation uptake.
Clinical Evidence
Clinical evidence
Preclinical research reports improved metabolic homeostasis, insulin sensitivity, and exercise capacity; human data are limited.
Human evidence (limited): Domin and colleagues (2023, International Journal of Molecular Sciences ) reported that higher serum MOTS-c levels correlated with greater lower-body muscle strength in healthy adults. This is a correlation in one small sample, not a randomized intervention trial. Phase 1 analog data: CB4211, a synthetic MOTS-c analog, completed a Phase 1a/1b trial reported as safe and well tolerated. The molecule is related but not identical, so this safety signal does not transfer fully to native MOTS-c. Preclinical evidence (strongest): Lee and colleagues (2015, Cell Metabolism ) showed MOTS-c reduced obesity and insulin resistance in mice on a high-fat diet. Reynolds and colleagues (2021, Nature Communications ) showed running capacity improvement across mouse age groups. Kumagai and colleagues (2021, American Journal of Physiology - Endocrinology and Metabolism ) reported reduced myostatin and atrophy signaling in mice. Yi and colleagues (2023, Frontiers in Physiology ) reviewed bone-metabolism findings. Mechanism review: Wan and colleagues (2023, Journal of Translational Medicine ) and Kong and colleagues (2023, Diabetes & Metabolism Journal ) reviewed AMPK activation, mitochondria-to-nucleus signaling, and the link between MOTS-c and aging-related metabolic disease. Evidence gap: No published human randomized controlled trial has tested native MOTS-c for any clinical endpoint. Treat the dose tiers on this page as research-planning context, not as proof of human benefit.
- 01MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded within the mitochondrial 12S rRNA region, studied as a regulator of metabolic homeostasis (mechanistic / in vitro).
- 02In cell and mouse studies, MOTS-c is associated with AMPK pathway activation and improved insulin sensitivity, including in diet-induced obese mice (in vitro / animal model; Lee et al., Cell Metabolism, 2015).
- 03MOTS-c has been described translocating to the nucleus under metabolic stress to influence adaptive gene expression (in vitro / animal model).
- 04Exercise research reports changes in circulating MOTS-c with physical activity, suggesting an association with exercise physiology (human observational / animal model).
- 05Direct human interventional trials for weight endpoints are not established; the weight-related evidence base is preclinical.
Evidence maturity varies by compound; much peptide research is preclinical (in vitro or animal-model). Where human data are limited, findings should be read as research observations, not clinical conclusions.
References
Literature references
Published research articles and sources related to MOTS-C.
- 01Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism (2015)et al. (2015)
- 02Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications (2021)et al. (2021)
- 03Kumagai H, Coelho AR, Wan J, et al. MOTS-c reduces myostatin and muscle atrophy signaling. American Journal of Physiology - Endocrinology and Metabolism (2021)et al. (2021)
- 04Wan W, Zhang L, Lin Y, et al. Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging. Journal of Translational Medicine (2023)et al. (2023)
- 05Kong BS, Lee C, Cho YM. Mitochondrial-encoded peptide MOTS-c, diabetes, and aging-related diseases. Diabetes & Metabolism Journal (2023)et al. (2023)
- 06Domin R, Pytka M, Niziolek-Szynczak A, et al. MOTS-c serum concentration positively correlates with lower-body muscle strength and is not related to maximal oxygen uptake — a preliminary study. International Journal of Molecular Sciences (2023)et al. (2023)
- 07Yi X, Hu G, Yang Y, et al. Role of MOTS-c in the regulation of bone metabolism. Frontiers in Physiology (2023)et al. (2023)
- 08Zhe W, Liu Y, Han P, et al. Central and peripheral mechanism of MOTS-c attenuates pain hypersensitivity in a mice model of inflammatory pain. Neurological Research (2024)et al. (2024)
- 09Yin Y, Pan Y, He J, et al. Mitochondrial-derived peptide MOTS-c suppresses ovarian cancer progression by attenuating USP7-mediated LARS1 deubiquitination. Advanced Science (2024)et al. (2024)
- 10U.S. Anti-Doping Agency. What is the MOTS-c peptide? USADA (2024)et al. (2024)
- 11World Anti-Doping Agency. The 2026 Prohibited List - Section S4.4 Metabolic Modulators (MOTS-c named under AMPK activators). WADA (2026)et al. (2026)
- 12U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A — MOTS-c removal from Category 2 (effective April 22, 2026); PCAC consultation scheduled July 23, 2026. FDA (2026)et al. (2026)
- 13Alzheimer's Drug Discovery Foundation. MOTS-c — Cognitive Vitality Report (notes CB4211 Phase 1 safety read-across). ADDF (2021)et al. (2021)
Observed Effects
Observed effects in cited research
Reported observations
- Injection site redness or swelling — Common — Rotate sites, inject slowly.
- Flushing or skin warmth (histamine response) — Occasional — Inject more slowly; consider lower dose for the first few sessions.
- Headache — Occasional — Stay hydrated; reduce dose if persistent.
- Mild fatigue after dose — Occasional — Lower dose or move dose to morning.
- Heart palpitations — Reported by USADA — Stop and seek qualified medical input.
- Insomnia or fever — Reported by USADA — Stop and seek qualified medical input.
Theoretical risks
- Cancer signaling. Some preclinical work shows MOTS-c slowing certain tumor lines (Yin 2024 ovarian cancer model). Other sources cited by Innerbody flag possible risk in prostate and breast cancer settings. Direction of effect is not settled, so an active cancer diagnosis is a hold reason.
- AMPK overlap. People on metformin, aspirin, or thiazolidinediones may layer AMPK activation, with unknown net effect.
- Quality variability. Research-grade peptides can include impurities. Immunogenicity (an unwanted immune reaction) is a stated risk in FDA materials on protein-based therapeutics.
Research Considerations
Research considerations
Research Use Only - not for human or veterinary therapeutic use. Current evidence is limited to in vitro and/or animal-model research; human data are minimal or absent. Consult a licensed healthcare professional for any clinical decisions.
- Glucose handling and insulin-sensitivity research, anchored to the Lee 2015 Cell Metabolism paper.
- Exercise capacity and aging research, anchored to the Reynolds 2021 Nature Communications paper.
- Bone metabolism research, summarized in the Yi 2023 Frontiers in Physiology review.
- Inflammation research, anchored to the Zhe 2024 Neurological Research paper on inflammatory pain models.
- Anyone with an active cancer diagnosis, since MOTS-c effects on tumor biology are mixed in the literature and clinician sources cited by Innerbody recommend caution.
- Pregnant or breastfeeding individuals, because there is no human safety data.
- People taking other AMPK-activating drugs such as metformin, thiazolidinediones, or aspirin without prescriber input, because of theoretical overlap.
- Athletes subject to drug testing under WADA rules, since MOTS-c is prohibited at all times under section S4.4.1.
- Anyone who would not have access to a clinician if a observed effect appeared.
Factors noted in the research literature; not patient-specific medical advice.
Regulatory Status
Regulatory status
RUO
Comparisons
Comparisons
| Compound | Mechanism | Route | Status |
|---|---|---|---|
| MOTS-Cthis | A 16-amino-acid mitochondrial-derived peptide encoded in the 12S rRNA region of mtDNA that activates AMPK and influences nuclear stress-response gene expression, studied for metabolic homeostasis. | subcutaneous | Investigational / RUO |
| Retatrutide | An investigational triple-receptor agonist targeting GLP-1, GIP, and glucagon receptors, combining appetite regulation, insulinotropic activity, and increased energy expenditure. | subcutaneous | Investigational / RUO |
| Semaglutide | Activates GLP-1 receptors to increase insulin secretion, slow gastric emptying, and reduce appetite through central mechanisms. | subcutaneous | Investigational / RUO |
| SLU-PP-332 | A synthetic pan-agonist of estrogen-related receptors (ERR alpha/beta/gamma) studied for activation of an aerobic-exercise-like gene program and increased oxidative metabolism. | — | Investigational / RUO |
| Survodutide | An investigational long-acting dual agonist of GLP-1 and glucagon receptors studied for appetite regulation and increased energy expenditure. | subcutaneous | Investigational / RUO |
| NAD+ | An essential coenzyme central to cellular energy metabolism (redox reactions) and mitochondrial function, and a substrate for sirtuins and PARPs in DNA-repair and signaling pathways. | subcutaneous | Investigational / RUO |
| Oxytocin | A nonapeptide hormone acting on oxytocin receptors; studied for roles in uterine contraction, lactation, and central modulation of social and affiliative behavior. | subcutaneous | Investigational / RUO |
Attributes shown for research comparison only; not a statement of efficacy or therapeutic equivalence.
FAQ
Frequently asked questions
MOTS-c is a 16-amino-acid peptide encoded by mitochondrial DNA. It activates AMPK, an enzyme that controls how cells use energy. The body makes more of it during exercise, and levels drop with age. It is not FDA-approved for human use.
MOTS-c is studied in metabolic health, exercise capacity, body composition, aging, bone metabolism, and inflammation. Most published evidence is from animal and cell models, with limited cross-sectional human data.
Common research-planning anchor is 5 mg subcutaneous, 2 to 3 times per week, in 4 to 8 week cycles. Lower-end planning is 5 mg twice weekly, higher-end is 10 mg two to three times weekly. None of these have been validated in a published human randomized trial. This is not a dosing recommendation.
Three tiers are commonly cited: a starting tier of 5 mg twice weekly for 4 weeks, a standard tier of 5 mg three times weekly for 4-6 weeks, and a higher tier of 10 mg two to three times weekly for 6-8 weeks. See the dosage chart table on this page for context. For a deeper dosing reference, also see Peptide Dosing Protocols .
A 10 mg vial reconstituted with 1.0 mL of bacteriostatic water gives a 10 mg/mL concentration. A 5 mg dose is 0.5 mL, which is 50 units on a U-100 insulin syringe. Swirl the vial gently rather than shaking, and refrigerate after mixing.
Cycles described in research planning are 4 to 8 weeks on, with an off period of similar length. Cycling is reported as a way to limit AMPK downregulation. There is no published human trial that has compared cycle lengths directly.
Reported observed effects include injection-site redness or swelling, flushing or skin warmth (a histamine response), mild fatigue, and headache. The U.S. Anti-Doping Agency monograph also lists heart palpitations, insomnia, and fever in people who buy it online. There is no large human safety database for native MOTS-c.
MOTS-c can trigger mast cell activation, which releases histamine and causes warmth, redness, or itching at or near the injection site. Slower injection and a lower starting dose can reduce it. Persistent reactions are a stop signal.
People with an active cancer diagnosis, anyone pregnant or breastfeeding, athletes subject to WADA testing, and people taking other AMPK-activating drugs (metformin, thiazolidinediones, aspirin) without prescriber input should avoid it. None of these groups have human safety data for MOTS-c.
MOTS-c works through AMPK and mitochondrial signaling. Tesamorelin works through growth hormone release and is FDA-approved for HIV-associated visceral fat. SS-31 targets the inner mitochondrial membrane through cardiolipin. They are studied for related goals but are not interchangeable.
No. MOTS-c is not FDA-approved for any human use as of June 2026. It was removed from FDA Category 2 effective April 22, 2026, and is scheduled for Pharmacy Compounding Advisory Committee discussion on July 23, 2026. Removal from Category 2 does not mean it is approved or that it is on the 503A Bulks List.
Yes. MOTS-c is named explicitly on the 2026 World Anti-Doping Agency (WADA) Prohibited List under section S4.4.1 (AMPK activators) and is prohibited at all times.
No. This page is an educational research reference. It is not medical advice, and it is not a treatment plan. Talk with a qualified healthcare provider before making any health decisions involving MOTS-c.
Research-use notice
Research Use Only. This educational content and calculation support is intended for private research documentation. It does not provide medical advice, human-use directions, or claims of safety or effectiveness.